-Related Anticancer Activities of Bulb Extracts Against Lung Cancer

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2022 Jun 30

PMID 35769912

Authors

K Laka

Z Mbita

Affiliations

Soon will be listed here.

Abstract

Current lung cancer treatment strategies are ineffective, and lung cancer cases continue to soar; thus, novel anticancer drugs and targets are needed, and medicinal plants are promising to offer better alternatives. This study was aimed at analysing two splice variants during the potential anticancer activities of () methanol and water extracts against different human lung cancer cell lines of varying mutation status, and these included mutant H1573 and mutant H1437 and -wild type (A549) cells. The anticancer activities of the extracts were assessed by establishing the cytotoxic effect and the apoptosis-inducing capacity of these extracts, using the MTT assay and Annexin V analysis, respectively, with the latter confirmed using fluorescence microscopy. The molecular mechanisms induced by these extracts were further evaluated using cell cycle analysis and RT-PCR. Both extracts demonstrated safety against noncancerous lung MRC-5 fibroblasts and exhibited significant anticancer potency ( < 0.001) against the H1437 (IC values: 62.50 μg/ml methanol extract and 125 μg/ml WE), H1573 (IC value: 125 μg/ml for both extracts) and A549 (IC value: 500 μg/ml ME). The water extract had no effect on the viability of A549 cells. Treated H1437 cells underwent -dependent apoptosis and S-phase cell cycle arrest while H1573 treated cells underwent -independed apoptosis and G0/G1 cell cycle arrest through upregulation of mRNA expression levels. The expression levels of , , and genes increased significantly ( < 0.001) following the treatment of H1573 cells with ME and WE. Treatment of H1437 cells with ME upregulated the , , and mRNAs. Our results indicate that the proliferative inhibitory effect of extracts on A549 and H1573 cells is correlated with the suppression of , and while that is not the case in H1437 cells. Thus, our results suggest that the dysregulation of anti-apoptotic molecules , , and in H1437 may play a role in cancer cell survival, which may consequently contribute to the development of -mutated non-small human lung cancer. Our results indicate that is a promising source of anticancer agents for the treatment of p53-mutant human non-small lung cancer cells than the p53-wild type human non-small lung cancer cells.

Citing Articles

GC-MS analysis, molecular docking, and apoptotic-based cytotoxic effect of Caladium lindenii Madison extracts toward the HeLa cervical cancer cell line.

Kalsoom A, Altaf A, Sarwar M, Maqbool T, Ashraf M, Sattar H Sci Rep. 2024; 14(1):18438.

PMID: 39117897 PMC: 11310479. DOI: 10.1038/s41598-024-69582-2.

References

Jovanovic K, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M . Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Front Oncol. 2019; 8:665. PMC: 6333636. DOI: 10.3389/fonc.2018.00665. View

Labbe C, Cabanero M, Korpanty G, Tomasini P, Doherty M, Mascaux C . Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017; 111:23-29. DOI: 10.1016/j.lungcan.2017.06.014. View

Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

Mandadi K, K Jayaprakasha G, Bhat N, Patil B . Red Mexican grapefruit: a novel source for bioactive limonoids and their antioxidant activity. Z Naturforsch C J Biosci. 2007; 62(3-4):179-88. DOI: 10.1515/znc-2007-3-405. View

Brito A, Areche C, Sepulveda B, Kennelly E, Simirgiotis M . Anthocyanin characterization, total phenolic quantification and antioxidant features of some Chilean edible berry extracts. Molecules. 2014; 19(8):10936-55. PMC: 6271127. DOI: 10.3390/molecules190810936. View

Street R, Stirk W, Van Staden J . South African traditional medicinal plant trade-Challenges in regulating quality, safety and efficacy. J Ethnopharmacol. 2008; 119(3):705-10. DOI: 10.1016/j.jep.2008.06.019. View

Li J, Hu L, Zhou T, Gong X, Jiang R, Li H . Taxifolin inhibits breast cancer cells proliferation, migration and invasion by promoting mesenchymal to epithelial transition via β-catenin signaling. Life Sci. 2019; 232:116617. DOI: 10.1016/j.lfs.2019.116617. View

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K . Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. Lung Cancer. 2019; 129:55-62. DOI: 10.1016/j.lungcan.2019.01.005. View

Kuete V, Efferth T . African flora has the potential to fight multidrug resistance of cancer. Biomed Res Int. 2015; 2015:914813. PMC: 4413252. DOI: 10.1155/2015/914813. View

10.

Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y . Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019; 62(5):640-647. DOI: 10.1007/s11427-018-9461-5. View

11.

Wu C, Sun Z, Ye Y, Han X, Song X, Liu S . Psoralen inhibits bone metastasis of breast cancer in mice. Fitoterapia. 2013; 91:205-210. DOI: 10.1016/j.fitote.2013.09.005. View

12.

Losuwannarak N, Maiuthed A, Kitkumthorn N, Leelahavanichkul A, Roytrakul S, Chanvorachote P . Gigantol Targets Cancer Stem Cells and Destabilizes Tumors via the Suppression of the PI3K/AKT and JAK/STAT Pathways in Ectopic Lung Cancer Xenografts. Cancers (Basel). 2019; 11(12). PMC: 6966687. DOI: 10.3390/cancers11122032. View

13.

Shi S, Deng Y, Zhao J, Ji X, Shi J, Feng Y . RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway. J Biol Chem. 2012; 287(11):7845-58. PMC: 3318742. DOI: 10.1074/jbc.M111.315416. View

14.

Laka K, Makgoo L, Mbita Z . Survivin Splice Variants in Arsenic Trioxide (As₂O₃)-Induced Deactivation of PI3K and MAPK Cell Signalling Pathways in MCF-7 Cells. Genes (Basel). 2019; 10(1). PMC: 6356383. DOI: 10.3390/genes10010041. View

15.

Tsurutani J, Fukuoka J, Tsurutani H, Shih J, Hewitt S, Travis W . Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol. 2005; 24(2):306-14. DOI: 10.1200/JCO.2005.02.4133. View

16.

Knittel D, Stintzing F, Kammerer D . Simultaneous determination of bufadienolides and phenolic compounds in sea squill (Drimia maritima (L.) Stearn) by HPLC-DAD-MSn as a means to differentiate individual plant parts and developmental stages. Anal Bioanal Chem. 2014; 406(24):6035-50. DOI: 10.1007/s00216-014-8008-0. View

17.

Baskiewicz-Masiuk M, Machalinski B . The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells. Eur J Haematol. 2004; 72(6):420-9. DOI: 10.1111/j.1600-0609.2004.00242.x. View

18.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

19.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

20.

Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T . Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2008; 4(1):22-9. DOI: 10.1097/JTO.0b013e3181914111. View